Publications on optical genome mapping in rare diseases rise 56% in Q1 2026, boosting genetic diagnosis.

Bionano Genomics reported a 56% increase in publications using optical genome mapping (OGM) for rare disease analysis in Q1 2026 compared to Q1 2025. The number of samples analyzed grew 225%, highlighting OGM's growing role in identifying structural variants missed by traditional methods. Studies from multiple countries show OGM improves diagnosis by resolving previously unexplained genetic cases and complements sequencing techniques. This advancement may accelerate research and treatment options for rare genetic disorders worldwide.